Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
Aim. To assess the long-term effectiveness and safety of moxonidine (Physiotens®), as antihypertensive treatment in patients with metabolic syndrome (MS), including women with menopausal MS. Material and methods. The study included 274 patients: 203 women (74 %) and 70 men (26 %). Postmenopausal wom...
Saved in:
| Main Authors: | E. V. Tishina, V. B. Mychka, Yu. V. Zhernakova, K. P. Ivanov, S. N. Tolstov, I. E. Chazova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-06-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
by: V. V. Trusov, et al.
Published: (2007-08-01) -
An imidazoline receptor agonist, moxonidine, in optimization of arterial hypertension treatment among postmenopausal women
by: A. B. Bakhshaliev, et al.
Published: (2006-02-01) -
Moxonidine-based combination antihypertensive therapy in patients with metabolic syndrome
by: E. V. Tishina, et al.
Published: (2012-06-01) -
IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?
by: D. V. Nebieridze, et al.
Published: (2015-12-01) -
ADDITIONAL BENEFITS OF ANTIHYPERTENSIVE MOXONIDINE THERAPY IN POSTMENOPAUSAL WOMEN WITH ARTERIAL HYPERTENSION
by: E. N. Dudinskaya, et al.
Published: (2014-02-01)